Dr. Abdel-Ghani Azzouqa
Claim this profileRapid City Regional Hospital
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
13 reported clinical trials
31 drugs studied
Area of expertise
1Lung Cancer
Stage IV
EGFR negative
ALK negative
2Non-Small Cell Lung Cancer
Stage IV
EGFR negative
ALK negative
Affiliated Hospitals
Clinical Trials Abdel-Ghani Azzouqa is currently running
Atezolizumab + Multi-Kinase Inhibitor
for Liver Cancer
This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to has spread to nearby tissue or lymph nodes (locally advanced), or has spread to other places in the body (metastatic), for which the patient has received treatment in the past (previously treated). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib and lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab with cabozantinib or lenvatinib may kill more tumor cells in patients with liver cancer.
Recruiting1 award Phase 23 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
More about Abdel-Ghani Azzouqa
Clinical Trial Related4 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Abdel-Ghani Azzouqa has experience with
- Nivolumab
- Cabozantinib
- Pembrolizumab
- Pemetrexed
- Atezolizumab
- Leucovorin Calcium
Breakdown of trials Abdel-Ghani Azzouqa has run
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Colorectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Abdel-Ghani Azzouqa specialize in?
Abdel-Ghani Azzouqa focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are EGFR negative.
Is Abdel-Ghani Azzouqa currently recruiting for clinical trials?
Yes, Abdel-Ghani Azzouqa is currently recruiting for 2 clinical trials in Rapid City South Dakota. If you're interested in participating, you should apply.
Are there any treatments that Abdel-Ghani Azzouqa has studied deeply?
Yes, Abdel-Ghani Azzouqa has studied treatments such as Nivolumab, Cabozantinib, Pembrolizumab.
What is the best way to schedule an appointment with Abdel-Ghani Azzouqa?
Apply for one of the trials that Abdel-Ghani Azzouqa is conducting.
What is the office address of Abdel-Ghani Azzouqa?
The office of Abdel-Ghani Azzouqa is located at: Rapid City Regional Hospital, Rapid City, South Dakota 57701 United States. This is the address for their practice at the Rapid City Regional Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.